Last reviewed · How we verify

Administration of etoricoxib

University of Regensburg · Phase 3 active Small molecule

Administration of etoricoxib is a Selective COX-2 inhibitor (coxib) Small molecule drug developed by University of Regensburg. It is currently in Phase 3 development for Rheumatoid arthritis, Osteoarthritis, Acute pain.

Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation.

Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation. Used for Rheumatoid arthritis, Osteoarthritis, Acute pain.

At a glance

Generic nameAdministration of etoricoxib
SponsorUniversity of Regensburg
Drug classSelective COX-2 inhibitor (coxib)
TargetCOX-2 (Cyclooxygenase-2)
ModalitySmall molecule
Therapeutic areaRheumatology / Pain Management
PhasePhase 3

Mechanism of action

Etoricoxib is a selective COX-2 inhibitor that preferentially blocks the COX-2 enzyme over COX-1, thereby reducing the synthesis of pro-inflammatory prostaglandins while theoretically sparing the protective prostaglandins produced by COX-1 in the gastrointestinal tract and kidneys. This selective inhibition provides anti-inflammatory, analgesic, and antipyretic effects with a potentially improved gastrointestinal safety profile compared to non-selective NSAIDs.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Administration of etoricoxib

What is Administration of etoricoxib?

Administration of etoricoxib is a Selective COX-2 inhibitor (coxib) drug developed by University of Regensburg, indicated for Rheumatoid arthritis, Osteoarthritis, Acute pain.

How does Administration of etoricoxib work?

Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation.

What is Administration of etoricoxib used for?

Administration of etoricoxib is indicated for Rheumatoid arthritis, Osteoarthritis, Acute pain, Ankylosing spondylitis.

Who makes Administration of etoricoxib?

Administration of etoricoxib is developed by University of Regensburg (see full University of Regensburg pipeline at /company/university-of-regensburg).

What drug class is Administration of etoricoxib in?

Administration of etoricoxib belongs to the Selective COX-2 inhibitor (coxib) class. See all Selective COX-2 inhibitor (coxib) drugs at /class/selective-cox-2-inhibitor-coxib.

What development phase is Administration of etoricoxib in?

Administration of etoricoxib is in Phase 3.

What are the side effects of Administration of etoricoxib?

Common side effects of Administration of etoricoxib include Hypertension, Edema, Dyspepsia, Headache, Cardiovascular events.

What does Administration of etoricoxib target?

Administration of etoricoxib targets COX-2 (Cyclooxygenase-2) and is a Selective COX-2 inhibitor (coxib).

Related